• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Syndax Pharmaceuticals Inc.

    4/30/26 5:22:09 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNDX alert in real time by email
    DEFA14A
    false0001395937DEFA14A00013959372025-01-012025-12-31

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.__)

    Filed by the Registrant  Filed by a party other than the Registrant 

    Check the appropriate box:

    

    Preliminary Proxy Statement

    

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    

    Definitive Proxy Statement

    

    Definitive Additional Materials

    

    Soliciting Material Pursuant to §240.14a-12

    Syndax Pharmaceuticals, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)

    Payment of Filing Fee (Check the appropriate box):

    

    No fee required.

    

    Fee paid previously with preliminary materials.

    

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


    img181013684_0.jpg


    img181013684_1.jpg


    Get the next $SNDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDX

    DatePrice TargetRatingAnalyst
    10/16/2025$40.00Buy
    H.C. Wainwright
    9/10/2025$44.00Buy
    Stifel
    9/4/2025$34.00Buy
    Guggenheim
    8/5/2025$43.00 → $56.00Buy
    BTIG Research
    7/10/2025$18.00Buy
    Goldman
    10/24/2024$37.00Buy
    UBS
    6/28/2024$37.00Buy
    Jefferies
    1/31/2024$36.00 → $23.00Sector Outperform → Sector Perform
    Scotiabank
    More analyst ratings

    $SNDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

    Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

    11/18/24 9:22:42 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Syndax Pharmaceuticals Inc.

    DEFA14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)

    6/4/26 8:36:41 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)

    6/4/26 7:16:36 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Syndax Pharmaceuticals Inc.

    DEFA14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)

    4/30/26 5:22:09 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company granted inducement awards to purchase up to 66,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About Syn

    6/4/26 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

    NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax") (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately negotiated subscription agreements for the issuance of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the "Notes"). The sale of the Notes is expected to close on June 10, 2026, subject to customary closing conditions. J. Wood Capital Advisors LLC is acting as sole placement agent in connection with the private placement of the Notes (the "private placement"). Syndax estimates that the net proceeds from the private placement will be approximatel

    6/4/26 7:00:00 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

    – Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a2-year overall survival rate of 90% vs historical benchmark of 51% – – Company also presented data highlighting unique aspects of revumenib's PK profile, including the ability to administer it with gastric acid reducing agents without the risk of reduced efficacy – NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today highlighted key Revuforj® (revumenib) data that was presented at the American Society

    6/2/26 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Syndax Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    10/16/25 8:20:22 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Syndax Pharmaceuticals with a new price target

    Stifel resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $44.00

    9/10/25 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim resumed coverage on Syndax Pharmaceuticals with a new price target

    Guggenheim resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $34.00

    9/4/25 9:08:04 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Goldan Keith A. sold $22,351 worth of shares (1,177 units at $18.99), decreasing direct ownership by 0.84% to 139,252 units (SEC Form 4) (for withholding tax)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    6/2/26 4:30:06 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Metzger Michael A sold $130,025 worth of shares (6,847 units at $18.99), decreasing direct ownership by 1% to 484,843 units (SEC Form 4) (withholding tax)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    6/2/26 4:30:02 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Metzger Michael A sold $360,819 worth of shares (17,159 units at $21.03), decreasing direct ownership by 3% to 491,690 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    2/10/26 9:00:18 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    5/19/25 4:04:07 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    5/19/25 4:03:03 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)

    4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)

    5/19/25 4:02:03 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Financials

    Live finance-specific insights

    View All

    Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

    – Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R NPM1m AML – – Niktimvo™ (axatilimab-csfr) net revenue of $55.1 million in 1Q26, resulting in Syndax collaboration revenue of $15.9 million – – New revumenib real-world, frontline, and post-HSCT maintenance data anticipated in 2Q26 – – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and newly diagnosed chronic GVHD – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX

    4/30/26 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

    NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Confere

    4/24/26 7:00:00 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6 million in FY2025, resulting in Syndax collaboration revenue of $42.4 million in FY2025 – – Completed enrollment in Phase 2 IPF trial of axatilimab; topline data expected in 4Q26 – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer ther

    2/26/26 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

    SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    11/8/24 10:52:38 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syndax Pharmaceuticals Inc.

    SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    10/18/24 11:49:10 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Syndax Pharmaceuticals Inc.

    SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    2/14/24 12:50:09 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNDX
    Leadership Updates

    Live Leadership Updates

    View All

    Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

    - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa

    5/12/25 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

    BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

    6/10/24 7:30:00 AM ET
    $PYXS
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

    WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo

    5/15/24 4:05:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care